ABSTRACT
Objectives Describe a new England-wide electronic health record (EHR) resource enabling whole population research on Covid-19 and cardiovascular disease whilst ensuring data security and privacy and maintaining public trust.
Design Cohort comprising linked person-level records from national healthcare settings for the English population accessible within NHS Digital’s new Trusted Research Environment.
Setting EHRs from primary care, hospital episodes, death registry, Covid-19 laboratory test results and community dispensing data, with further enrichment planned from specialist intensive care, cardiovascular and Covid-19 vaccination data.
Participants 54.4 million people alive on 1st January 2020 and registered with an NHS general practitioner in England.
Main measures of interest Confirmed and suspected Covid-19 diagnoses, exemplar cardiovascular conditions (incident stroke or transient ischaemic attack (TIA) and incident myocardial infarction (MI)) and all-cause mortality between 1st January and 31st October 2020.
Results The linked cohort includes over 96% of the English population. By combining person-level data across national healthcare settings, data on age, sex and ethnicity are complete for over 95% of the population. Among 53.2M people with no prior diagnosis of stroke/TIA, 98,721 had an incident stroke/TIA, of which 30% were recorded only in primary care and 4% only in death registry records. Among 53.1M people with no prior history of MI, 62,966 had an incident MI, of which 8% were recorded only in primary care and 12% only in death records. A total of 959,067 people had a confirmed or suspected Covid-19 diagnosis (714,162 in primary care data, 126,349 in hospital admission records, 776,503 in Covid-19 laboratory test data and 48,433 participants in death registry records). While 58% of these were recorded in both primary care and Covid-19 laboratory test data, 15% and 18% respectively were recorded in only one.
Conclusions This population-wide resource demonstrates the importance of linking person-level data across health settings to maximize completeness of key characteristics and to ascertain cardiovascular events and Covid-19 diagnoses. Although established initially to support research on Covid-19 and cardiovascular disease to benefit clinical care and public health and to inform health care policy, it can broaden further to enable a very wide range of research.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Registered on the Health Data Research UK Innovation Gateway: CVD-COVID-UK TRE asset in Health Data Research Innovation Gateway [Internet]. [cited 2021 Feb 18]. Available from: https://web.www.healthdatagateway.org/dataset/7e5f0247-f033-4f98-aed3-3d7422b9dc6d
Clinical Protocols
https://portal.caliberresearch.org/collections/bhf-data-science-centre
Funding Statement
The BHF Data Science Centre (BHF Grant no. SP/19/3/34678, awarded to Health Data Research UK) funded co-development (with NHS Digital) of the TRE, provision of linked datasets, data access, user software licences, computational usage and data management and wrangling support, with additional contributions from the HDR UK Data and Connectivity component of the UK Chief Scientific Adviser National Core Studies programme to coordinate national Covid-19 priority research. Consortium partner organisations funded the time of contributing data analysts, biostatisticians, epidemiologists and clinicians. The results described are based on data from patients, collected by the NHS as part of their care and support. We would also like to acknowledge all data providers who make anonymised data available for research. AA is supported by Health Data Research UK [HDR-9006] which receives its funding from the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation (BHF) and the Wellcome Trust; and Administrative Data Research UK which is funded by the Economic and Social Research Council [grant ES/S007393/1]. AB is supported by research funding from NIHR, British Medical Association, Astra-Zeneca and UK Research and Innovation. AB, AW and SD are part of the BigData@Heart Consortium, funded by the Innovative Medicines Initia-tive-2 Joint Undertaking under grant agreement No. 116074. AW and SI are supported by the BHF-Turing Cardiovascular Data Science Award (BCDSA\100005) and by core funding from: UK Medical Research Council (MR/L003120/1), British Heart Foundation (RG/13/13/30194; RG/18/13/33946) and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). JC, JS and RD are supported by the HDRUK South West Better Care Partnership and NIHR Bristol Biomedical Research Centre. SD is supported by Health Data Research UK London, which receives its funding from Health Data Research UK Ltd funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation, and the Wellcome Trust; Alan Turing Fellow-ship (EP/N510129/1); National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at University College London Hospital NHS Trust (UCLH). VW is supported by the University of Bristol Medical Research Council Integrative Epidemiology Unit (MC_UU_00011/4). WW is supported by a Scottish Senior Clinical Fellowship, CSO (SCAF/17/01)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The North East - Newcastle & North Tyneside 2 Research Ethics Committee provided ethical approval for the CVD-COVID-UK research programme (REC number: 20/NE/0161).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Consortium membership: https://www.hdruk.ac.uk/wp-content/uploads/2021/01/210128-CVD-COVID-UK-Consortium-Members.pdf and see Annexe 1 – Consortium members, who contributed to discussions leading up to this manuscript and provided very helpful insights and comments
Typo in discussion corrected: 200,000 people under 30 replaced with 20 million
Data Availability
Data are available for bona fide researchers accessible within the NHS Digital trusted Research Environment for England. Contact bhfdsc@hdruk.ac.uk for information on how to join the CVD-COVID-UK consortium for access.
https://web.www.healthdatagateway.org/dataset/7e5f0247-f033-4f98-aed3-3d7422b9dc6d
